• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Vaxart Inc

    1/19/24 4:30:58 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VXRT alert in real time by email
    SC 13G 1 tm243724d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    VAXART, INC.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)

     

    92243A200

    (CUSIP Number)

     

    January 18, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 92243A200

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF 5

    SOLE VOTING POWER

     

    0

    SHARES

    BENEFICIALLY

    OWNED BY

    6

    SHARED VOTING POWER

     

    15,384,615

    EACH

    REPORTING

    PERSON

    7

    SOLE DISPOSITIVE POWER

     

    0

    WITH: 8

    SHARED DISPOSITIVE POWER

     

    15,384,615

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,384,615

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.1%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

           

     

     

     

    CUSIP No. 92243A200

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF 5

    SOLE VOTING POWER

     

    0

    SHARES

    BENEFICIALLY

    OWNED BY

    6

    SHARED VOTING POWER

     

    15,384,615

    EACH

    REPORTING

    PERSON

    7

    SOLE DISPOSITIVE POWER

     

    0

    WITH: 8

    SHARED DISPOSITIVE POWER

     

    15,384,615

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,384,615

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.1%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN, HC

           

     

     

     

    CUSIP No. 92243A200

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF 5

    SOLE VOTING POWER

     

    0

    SHARES

    BENEFICIALLY

    OWNED BY

    6

    SHARED VOTING POWER

     

    15,384,615

    EACH

    REPORTING

    PERSON

    7

    SOLE DISPOSITIVE POWER

     

    0

    WITH: 8

    SHARED DISPOSITIVE POWER

     

    15,384,615

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,384,615

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.1%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN, HC

           

     

     

     

    CUSIP No. 92243A200

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF 5

    SOLE VOTING POWER

     

    0

    SHARES

    BENEFICIALLY

    OWNED BY

    6

    SHARED VOTING POWER

     

    15,384,615

    EACH

    REPORTING

    PERSON

    7

    SOLE DISPOSITIVE POWER

     

    0

    WITH: 8

    SHARED DISPOSITIVE POWER

     

    15,384,615

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,384,615

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.1%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

           

     

     

     

    Item 1(a).Name of Issuer:

     

    Vaxart, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    170 Harbor Way, Suite 300, South San Francisco CA 94080

     

    Item 2(a).Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    RA Capital Management, L.P. (“RA Capital”)

    Peter Kolchinsky

    Rajeev Shah

    RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

    RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, $0.0001 par value per share (“Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    92243A200

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

     

     

     

    Item 4.Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The beneficial ownership percentages reported are based on 168,837,448 outstanding Common Stock shares, as reported in the Issuer’s Prospectus filed on January 18, 2024 with the Securities and Exchange Commission.

     

    The Fund directly holds 15,384,615 shares of Common Stock.

     

    RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the shares of the Issuer’s Common Stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    Exhibit List

     

    Exhibit 1: Joint Filing Agreement

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:January 18, 2024

     

    RA CAPITAL MANAGEMENT, L.P.

     

    By:/s/Peter Kolchinsky  
     Name:Peter Kolchinsky  
     Title: Authorized Signatory  

     

    PETER KOLCHINSKY

     

    /s/ Peter Kolchinsky  

     

    RAJEEV SHAH

     

    /s/ Rajeev Shah  

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By:RA Capital Healthcare Fund GP, LLC  

    Its:General Partner  

     

    By:/s/ Peter Kolchinsky  
     Name:Peter Kolchinsky  
     Title: Manager  

     

     

     

     

    EXHIBIT 1

     

    AGREEMENT

     

    This Joint Filing Agreement, dated as of January 18, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).

     

    Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock, $0.0001 par value per share of Vaxart, Inc. beneficially owned by them from time to time.

     

    Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

     

    This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

     

    Executed and delivered as of the date first above written.

     

    RA CAPITAL MANAGEMENT, L.P.

     

    By:/s/ Peter Kolchinsky  
     Name: Peter Kolchinsky  
     Title: Authorized Signatory  

     

    PETER KOLCHINSKY

     

    /s/ Peter Kolchinsky  

     

    RAJEEV SHAH

     

    /s/ Rajeev Shah  

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By:RA Capital Healthcare Fund GP, LLC  

    Its:General Partner  

     

    By:/s/ Peter Kolchinsky  
     Name: Peter Kolchinsky  
     Title: Manager  

     

     

     

    Get the next $VXRT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VXRT

    DatePrice TargetRatingAnalyst
    8/15/2024$4.00Outperform
    Oppenheimer
    12/29/2021$13.00 → $12.00Buy
    Jefferies
    11/2/2021$15.00Overweight
    Cantor Fitzgerald
    6/30/2021$13.00 → $9.00Buy → Neutral
    B. Riley Securities
    6/29/2021$13.00 → $9.00Buy → Neutral
    B. Riley Securities
    6/24/2021$13.00Buy
    Jefferies
    More analyst ratings

    $VXRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vaxart Inc (Amendment)

      SC 13G/A - Vaxart, Inc. (0000072444) (Subject)

      2/13/24 5:16:04 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Vaxart Inc

      SC 13G - Vaxart, Inc. (0000072444) (Subject)

      1/19/24 4:30:58 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Vaxart Inc

      SC 13G - Vaxart, Inc. (0000072444) (Subject)

      2/9/23 11:35:17 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

      SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00 PM ET. A live webcast of the fireside chat will be available on the Company's website at www.vaxart.com or by clicking here. A replay of the fireside chat will be available for 30 days following the conclusion of the event. Investors interested in meeting with management during the conference may

      5/29/25 4:05:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

      Dr. Sean Tucker, Founder and CSO of Vaxart, Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 Company Corrects Record on Common Misconceptions Regarding the Reverse Stock Split Proposal SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" OR "Vaxart") today announces a video update for stockholders by Dr. Sean Tucker. The video is available on Vaxart's investor relations website at investors.vaxart.com. In the video, Dr. Tucker urges stockholders to vote FOR Proposal No. 2, which grants the Board of Directors authority to implement a reverse split that would enable Vaxart regain compli

      5/29/25 8:00:20 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Answers Additional Frequently Asked Questions from Retail Investors

      Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" OR "Vaxart") today answers additional frequently asked stockholder questions it has received from retail investors in advance of the Company's Annual Meeting of Stockholders scheduled to take place on Monday, June 2, 2025. "We appreciate the continued interest from our passionate and loyal stockholder base," said Steven Lo, Chief Executive Officer of Vaxart. "Understanding their concerns and directly addressing their most frequently asked questions, we are hopeful that thi

      5/28/25 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Grasman Jeroen Nicolaas was granted 350,000 shares (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      5/20/25 10:45:14 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Grasman Jeroen Nicolaas

      3 - Vaxart, Inc. (0000072444) (Issuer)

      5/20/25 10:43:43 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President, Chief Exec Officer Lo Steven bought $49,000 worth of shares (100,000 units at $0.49) (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      5/19/25 6:49:39 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Vaxart with a new price target

      Oppenheimer initiated coverage of Vaxart with a rating of Outperform and set a new price target of $4.00

      8/15/24 7:45:56 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies resumed coverage on Vaxart with a new price target

      Jefferies resumed coverage of Vaxart with a rating of Buy and set a new price target of $12.00 from $13.00 previously

      12/29/21 7:23:57 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Vaxart with a new price target

      Cantor Fitzgerald initiated coverage of Vaxart with a rating of Overweight and set a new price target of $15.00

      11/2/21 7:42:45 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Leadership Updates

    Live Leadership Updates

    See more
    • Vaxart Appoints Jeroen Grasman as Chief Financial Officer

      - Mr. Grasman brings over two decades of biotech financial leadership experience - SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced the appointment of Jeroen Grasman as its Chief Financial Officer (CFO), effective May 19, 2025. Mr. Grasman succeeds Phillip Lee, who is resigning from his position as CFO for personal reasons. To ensure a smooth transition, Mr. Lee will remain with the Company as a non-executive employee through June 1, 2025. "We are delighted to welcome Jeroen to the Vaxart team," said Steven Lo, Chief Executive Officer of Vaxart. "His extensive financial expertise and proven track record in the biotech sector, includ

      5/13/25 4:01:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

      Mr. Finney brings 35 years of leadership, operations and corporate development experience SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced the appointment of Kevin Finney to the Company's Board of Directors, effective today. Mr. Finney is a seasoned healthcare executive and experienced board member who brings decades of industry leadership experience and operational expertise. Mr. Finney will serve as a member of the Audit and Nominating and Governance Committees of the Board. "Kevin adds a wealth of healthcare industry experience spanning executive leadership, governance, operations, and corporate deve

      1/28/25 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

      Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced that it has appointed Steven Lo as President and Chief Executive Officer and a member of the Board of Directors, effective as of March 18, 2024. Mr. Lo is a highly experienced biopharma executive with over 25 years of experience in the healthcare, biotechnology, and pharmaceutical industries, including over 12 years of C-level experience in publicly traded biotech companies. Michael J. Finney, Ph.D. will step down as interim Chief Executive Officer and will continue to serve as Ch

      3/6/24 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, Chief Exec Officer Lo Steven bought $49,000 worth of shares (100,000 units at $0.49) (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      5/19/25 6:49:39 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Watson W. Mark bought $13,578 worth of shares (20,000 units at $0.68), increasing direct ownership by 34% to 78,125 units (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      6/20/24 6:10:10 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Vaxart Inc

      DEFA14A - Vaxart, Inc. (0000072444) (Filer)

      5/29/25 2:58:48 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Vaxart Inc

      PRE 14A - Vaxart, Inc. (0000072444) (Filer)

      5/29/25 10:14:08 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Vaxart, Inc. (0000072444) (Filer)

      5/28/25 2:58:45 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Financials

    Live finance-specific insights

    See more
    • Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

      Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, with topline data expected in mid-2025 New avian influenza vaccine candidate was 100% protective in a ferret challenge model, compared with 0% survival in placebo-treated animals Jeroen Grasman appointed as Chief Financial Officer effective May 19, 2025 Cash, cash equivalents and investments of $41.9 million as of March 31, 2025; Current runway into 2026 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 13, 2025 (

      5/13/25 4:05:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

      Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Tuesday, May 13, 2025 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13753354 Investors may submit written questions in advance of the confer

      5/2/25 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

      Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort Cash, cash equivalents and investments of $51.7 million as of December 31, 2024 provides runway through multiple development milestones and into the fourth quarter of 2025 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the full year 2024. "Since our founding, Vaxart has been on a mission to transform glo

      3/20/25 4:01:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care